|
1
|
Xing M, Haugen BR and Schlumberger M:
Progress in molecular-based management of differentiated thyroid
cancer. Lancet. 381:1058–1069. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kelly LM, Barila G, Liu P, Evdokimova VN,
Trivedi S, Panebianco F, Gandhi M, Carty SE, Hodak SP, Luo J, et
al: Identification of the transforming STRN-ALK fusion as a
potential therapeutic target in the aggressive forms of thyroid
cancer. Proc Natl Acad Sci USA. 111:4233–4238. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McLeod DS, Sawka AM and Cooper DS:
Controversies in primary treatment of low-risk papillary thyroid
cancer. Lancet. 381:1046–1057. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Van Fossen VL, Wilhelm SM, Eaton JL and
McHenry CR: Association of thyroid, breast and renal cell cancer: A
population-based study of the prevalence of second malignancies.
Ann Surg Oncol. 20:1341–1347. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tatler AL, Habgood A, Porte J, John AE,
Stavrou A, Hodge E, Kerama-Likoko C, Violette SM, Weinreb PH, Knox
AJ, et al: Reduced Ets Domain-containing protein Elk1 promotes
pulmonary fibrosis via increased integrin αvβ6 expression. J Biol
Chem. 291:9540–9553. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Buffet C, Catelli MG, Hecale-Perlemoine K,
Bricaire L, Garcia C, Gallet-Dierick A, Rodriguez S, Cormier F and
Groussin L: Dual specificity phosphatase 5, a specific negative
regulator of ERK signaling, is induced by serum response factor and
Elk-1 transcription factor. PLoS One. 10:e01454842015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morris JF, Sul JY, Kim MS, Klein-Szanto
AJ, Schochet T, Rustgi A and Eberwine JH: Elk-1 phosphorylated at
threonine-417 is present in diverse cancers and correlates with
differentiation grade of colonic adenocarcinoma. Hum Pathol.
44:766–776. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Glidewell-Kenney CA, Trang C, Shao PP,
Gutierrez-Reed N, Uzo-Okereke AM, Coss D and Mellon PL: Neurokinin
B induces c-fos transcription via protein kinase C and activation
of serum response factor and Elk-1 in immortalized GnRH neurons.
Endocrinology. 155:3909–3919. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen YS, Aubee J, DiVito KA, Zhou H, Zhang
W, Chou FP, Simbulan-Rosenthal CM and Rosenthal DS: Id3 induces an
Elk-1-caspase-8-dependent apoptotic pathway in squamous carcinoma
cells. Cancer Med. 4:914–924. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kawahara T, Shareef HK, Aljarah AK, Ide H,
Li Y, Kashiwagi E, Netto GJ, Zheng Y and Miyamoto H: ELK1 is
up-regulated by androgen in bladder cancer cells and promotes tumor
progression. Oncotarget. 6:29860–29876. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Patki M, Chari V, Sivakumaran S, Gonit M,
Trumbly R and Ratnam M: The ETS domain transcription factor ELK1
directs a critical component of growth signaling by the androgen
receptor in prostate cancer cells. J Biol Chem. 288:11047–11065.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim HR, Lee HN, Lim K, Surh YJ and Na HK:
15-Deoxy-Δ12,14-prostaglandin J2 induces expression of
15-hydroxyprostaglandin dehydrogenase through Elk-1 activation in
human breast cancer MDA-MB-231 cells. Mutat Res. 768:6–15. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hsu YL, Hou MF, Kuo PL, Huang YF and Tsai
EM: Breast tumor-associated osteoblast-derived CXCL5 increases
cancer progression by ERK/MSK1/Elk-1/snail signaling pathway.
Oncogene. 32:4436–4447. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goncharenko-Khaider N, Matte I, Lane D,
Rancourt C and Piche A: Ovarian cancer ascites increase Mcl-1
expression in tumor cells through ERK1/2-Elk-1 signaling to
attenuate TRAIL-induced apoptosis. Mol Cancer. 11:842012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Demir O and Kurnaz IA: Wildtype Elk-1, but
not a SUMOylation mutant, represses egr-1 expression in SH-SY5Y
neuroblastomas. Neurosci Lett. 437:20–24. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pacini L, Suffredini S, Ponti D, Coppini
R, Frati G, Ragona G, Cerbai E and Calogero A: Altered calcium
regulation in isolated cardiomyocytes from Egr-1 knock-out mice.
Can J Physiol Pharmacol. 91:1135–1142. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zalcman G, Federman N, de la Fuente V and
Romano A: Nuclear factor kappa B-dependent Zif268 expression in
hippocampus is required for recognition memory in mice. Neurobiol
Learn Mem. 119:10–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fan YY, Ye GH, Lin KZ, Yu LS, Wu SZ, Dong
MW, Han JG, Feng XP and Li XB: Time-dependent expression and
distribution of Egr-1 during skeletal muscle wound healing in rats.
J Mol Histol. 44:75–81. 2013.PubMed/NCBI
|
|
19
|
Klenke S, Rump K, Buschkamp K, Engler A,
Peters J, Siffert W and Frey UH: Characterization of the PLCB1
promoter and regulation by early growth response transcription
factor EGR-1. Eur J Pharmacol. 742:8–14. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bhattacharyya S, Fang F, Tourtellotte W
and Varga J: Egr-1: New conductor for the tissue repair orchestra
directs harmony (regeneration) or cacophony (fibrosis). J Pathol.
229:286–297. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Witham EA, Meadows JD, Hoffmann HM,
Shojaei S, Coss D, Kauffman AS and Mellon PL: Kisspeptin regulates
gonadotropin genes via immediate early gene induction in pituitary
gonadotropes. Mol Endocrinol. 27:1283–1294. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sysol JR, Natarajan V and Machado RF: PDGF
induces SphK1 expression via Egr-1 to promote pulmonary artery
smooth muscle cell proliferation. Am J Physiol Cell Physiol.
310:C983–C992. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu QF, Yu HW, You L, Liu MX, Li KY and
Tao GZ: Apelin-13-induced proliferation and migration induced of
rat vascular smooth muscle cells is mediated by the upregulation of
Egr-1. Biochem Biophys Res Commun. 439:235–240. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fang F, Shangguan AJ, Kelly K, Wei J,
Gruner K, Ye B, Wang W, Bhattacharyya S, Hinchcliff ME,
Tourtellotte WG and Varga J: Early growth response 3 (Egr-3) is
induced by transforming growth factor-β and regulates fibrogenic
responses. Am J Pathol. 183:1197–1208. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim K, Jutooru I, Chadalapaka G, Johnson
G, Frank J, Burghardt R, Kim S and Safe S: HOTAIR is a negative
prognostic factor and exhibits pro-oncogenic activity in pancreatic
cancer. Oncogene. 32:1616–1625. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim JH, Choi DS, Lee OH, Oh SH, Lippman SM
and Lee HY: Antiangiogenic antitumor activities of IGFBP-3 are
mediated by IGF-independent suppression of Erk1/2 activation and
Egr-1-mediated transcriptional events. Blood. 118:2622–2631. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Calogero A, Arcella A, De Gregorio G,
Porcellini A, Mercola D, Liu C, Lombari V, Zani M, Giannini G,
Gagliardi FM, et al: The early growth response gene EGR-1 behaves
as a suppressor gene that is down-regulated independent of ARF/Mdm2
but not p53 alterations in fresh human gliomas. Clin Cancer Res.
7:2788–2796. 2001.PubMed/NCBI
|
|
28
|
Vockerodt M, Wei W, Nagy E, Prouzova Z,
Schrader A, Kube D, Rowe M, Woodman CB and Murray PG: Suppression
of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells
from entry to the EBV lytic cycle. J Pathol. 230:399–409. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Scharnhorst V, Menke AL, Attema J,
Haneveld JK, Riteco N, van Steenbrugge GJ, van der Eb AJ and
Jochemsen AG: EGR-1 enhances tumor growth and modulates the effect
of the Wilms' tumor 1 gene products on tumorigenicity. Oncogene.
19:791–800. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Virolle T, Adamson ED, Baron V, Birle D,
Mercola D, Mustelin T and de Belle I: The Egr-1 transcription
factor directly activates PTEN during irradiation-induced
signalling. Nat Cell Biol. 3:1124–1128. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Salmena L: PTEN: History of a tumor
suppressor. Methods Mol Biol. 1388:3–11. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jing X, Cheng W, Wang S, Li P and He L:
Resveratrol induces cell cycle arrest in human gastric cancer
MGC803 cells via the PTEN-regulated PI3K/Akt signaling pathway.
Oncol Rep. 35:472–478. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jolly LA, Novitskiy S, Owens P, Massoll N,
Cheng N, Fang W, Moses HL and Franco AT: Fibroblast-mediated
collagen remodeling within the tumor microenvironment facilitates
progression of thyroid cancers driven by BrafV600E and pten loss.
Cancer Res. 76:1804–1813. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang Z, Yuan XG, Chen J, Luo SW, Luo ZJ
and Lu NH: Reduced expression of PTEN and increased PTEN
phosphorylation at residue Ser380 in gastric cancer tissues: A
novel mechanism of PTEN inactivation. Clin Res Hepatol
Gastroenterol. 37:72–79. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Govatati S, Kodati VL, Deenadayal M,
Chakravarty B, Shivaji S and Bhanoori M: Mutations in the PTEN
tumor gene and risk of endometriosis: A case-control study. Hum
Reprod. 29:324–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fortin J, Bassi C and Mak TW: PTEN enables
the development of pre-B acute lymphoblastic leukemia. Nat Med.
22:339–340. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Herranz D, Maraver A, Cañamero M,
Gómez-López G, Inglada-Pérez L, Robledo M, Castelblanco E,
Matias-Guiu X and Serrano M: SIRT1 promotes thyroid carcinogenesis
driven by PTEN deficiency. Oncogene. 32:4052–4056. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Weng LP, Gimm O, Kum JB, Smith WM, Zhou
XP, Wynford-Thomas D, Leone G and Eng C: Transient ectopic
expression of PTEN in thyroid cancer cell lines induces cell cycle
arrest and cell type-dependent cell death. Hum Mol Genet.
10:251–258. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Curcio F, Ambesi-Impiombato FS, Perrella G
and Coon HG: Long-term culture and functional characterization of
follicular cells from adult normal human thyroids. Proc Natl Acad
Sci USA. 91:9004–9008. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Welsh JB, Sapinoso LM, Su AI, Kern SG,
Wang-Rodriguez J, Moskaluk CA, Frierson HF Jr and Hampton GM:
Analysis of gene expression identifies candidate markers and
pharmacological targets in prostate cancer. Cancer Res.
61:5974–5978. 2001.PubMed/NCBI
|
|
41
|
Jankovic B, Le KT and Hershman JM:
Clinical review: Hashimoto's thyroiditis and papillary thyroid
carcinoma: Is there a correlation? J Clin Endocrinol Metab.
98:474–482. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wozniak MA, Cheng CQ, Shen CJ, Gao L,
Olarerin-George AO, Won KJ, Hogenesch JB and Chen CS: Adhesion
regulates MAP kinase/ternary complex factor exchange to control a
proliferative transcriptional switch. Curr Biol. 22:2017–2026.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Doma E, Rupp C, Varga A, Kern F, Riegler B
and Baccarini M: Skin tumorigenesis stimulated by Raf inhibitors
relies upon Raf functions that are dependent and independent of
ERK. Cancer Res. 73:6926–6937. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kawahara T, Aljarah AK, Shareef HK, Inoue
S, Ide H, Patterson JD, Kashiwagi E, Han B, Li Y, Zheng Y and
Miyamoto H: Silodosin inhibits prostate cancer cell growth via ELK1
inactivation and enhances the cytotoxic activity of gemcitabine.
Prostate. 76:744–756. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chakraborty T, Asok A, Stanton ME and
Rosen JB: Variants of contextual fear conditioning induce
differential patterns of Egr-1 activity within the young adult
prefrontal cortex. Behav Brain Res. 302:122–130. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Peralta-Zaragoza O, Deas J, Meneses-Acosta
A, De la O-Gómez F, Fernández-Tilapa G, Gómez-Cerón C,
Benítez-Boijseauneau O, Burguete-García A, Torres-Poveda K,
Bermúdez-Morales VH, et al: Relevance of miR-21 in regulation of
tumor suppressor gene PTEN in human cervical cancer cells. BMC
Cancer. 16:2152016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yang SM, Huang C, Li XF, Yu MZ, He Y and
Li J: miR-21 confers cisplatin resistance in gastric cancer cells
by regulating PTEN. Toxicology. 306:162–168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Soubani O, Ali AS, Logna F, Ali S, Philip
PA and Sarkar FH: Re-expression of miR-200 by novel approaches
regulates the expression of PTEN and MT1-MMP in pancreatic cancer.
Carcinogenesis. 33:1563–1571. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wu Z, He B, He J and Mao X: Upregulation
of miR-153 promotes cell proliferation via downregulation of the
PTEN tumor suppressor gene in human prostate cancer. Prostate.
73:596–604. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Guigon CJ, Zhao L, Willingham MC and Cheng
SY: PTEN deficiency accelerates tumour progression in a mouse model
of thyroid cancer. Oncogene. 28:509–517. 2009. View Article : Google Scholar : PubMed/NCBI
|
